Citations

Clear

163 citation(s) found for "Sharp, H L".

Communicating with Biobank Participants: Preferences for Receiving and Providing Updates to Researchers
Mester, Jessica L. , Mercer, MaryBeth, Goldenberg, Aaron J. , Moore, Rebekah , Sharp, Richard R. , Mercer, MaryBeth, Eng, Charis , Sharp, Richard R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 19, 2015 | Volume: 24 | Issue: 4 | Pages: 708-712

10.1158/1055-9965.epi-13-1375 | PMID 25597748 Get It

Abstract Background: Research biobanks collect biologic samples and health information. Previous work shows that biobank participants desire general study updates, but preferences about the method or frequency of these communications have not been explored. Thus, we surveyed participants in a long-standing research biobank. Methods: Eligible participants were drawn from a study of patients with personal/family history suggestive of Cowden syndrome, a poorly recognized inherited cancer syndrome. Participants gave blood samples and access to medical records and received individual results but had no other study interactions. The biobank had 3,618 participants at sampling. Survey eligibility included age ≥18 years, enrollment within the biobank's first 5 years, normal PTEN analysis, and contiguous U.S. address. Multivariate logistic regression analyses identified predictors of participant interest in Internet-based versus offline methods and methods allowing participant–researcher interaction versus one-way communication. Independent variables were narrowed by independent Pearson correlations by cutoff P < 0.2, with P < 0.02 considered significant. Results: Surveys were returned from 840 of 1,267 (66%) eligible subjects. Most (97%) wanted study updates, with 92% wanting updates at least once a year. Participants preferred paper (66%) or emailed (62%) newsletter methods, with 95% selecting one of these. Older, less-educated, and lower-income respondents strongly preferred offline approaches (P < 0.001). Most (93%) had no concerns about receiving updates and 97% were willing to provide health updates to researchers. Conclusion: Most participants were comfortable receiving and providing updated information. Demographic factors predicted communication preferences. Impact: Researchers should make plans for ongoing communication early in study development and funders should support the necessary infrastructure for these efforts. Cancer Epidemiol Biomarkers Prev; 24(4); 708–12. ©2015 AACR.
Why brain death is considered death and why there should be no confusion
Burkle, Christopher M. , Sharp, Richard R. , Wijdicks, Eelco F., Wijdicks, Eelco F. M. , Sharp, Richard R

Mayo Clinic

Neurology | September 13, 2014 | Volume: 83 | Issue: 16 | Pages: 1464-1469

10.1212/wnl.0000000000000883 | PMID 25217058 Get It

Changes in the Care of Non–Small-Cell Lung Cancer After Audit and Feedback: The Florida Initiative for Quality Cancer Care
Lee, Ji‐Hyun , Fulp, William J. , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George P., Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Malafa, Mokenge P. , Jacobsen, Paul B. , Tanvetyanon, Tawee , Brown, Richard H, Abesada-Terk, Guillermo, Sharp, Philip V, Malafa, Mokenge, Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | July 18, 2014 | Volume: 10 | Issue: 4 | Pages: e247-e254

10.1200/jop.2013.001275 | PMID 24737876 Get It

This study is among the first to report on the use of audit and feedback to improve medical oncology practices specifically for the processes of care in NSCLC. A modest but important improvement was observed between 2006 and 2009.
Managing expectational language: translational genetic professionals consider the clinical potential of next-generation sequencing technologies
Koay, Pei P. , Sharp, Richard R. , Sharp, Richard R

Mayo Clinic

New Genetics and Society | May 19, 2014 | Volume: 33 | Issue: 2 | Pages: 126-148

10.1080/14636778.2014.910448 | PMID 24883042 Get It

Next-generation Disadvantages: Identifying Potential Barriers to Integrating Genomics into Underserved Medical Settings
Goldenberg, Aaron J. , Marshall, Patricia A., Sharp, Richard R. , Sharp, Richard R

Mayo Clinic

Personalized Medicine | September 11, 2013 | Volume: 10 | Issue: 7 | Pages: 623-625

10.2217/pme.13.75 | PMID 29768757 Get It

‘Someone should oversee it’: patient perspectives on the ethical issues arising with the regulation of probiotics
Harrison, Krista L. , Farrell, Ruth M. , Brinich, Margaret A., Highland, Janelle, Mercer, MaryBeth, Tilburt, Jon C. , Geller, Gail , Marshall, Patricia A., Sharp, Richard R. , McCormick, Jennifer Blair , Sharp, Richard R

Mayo Clinic

Health Expectations | December 28, 2012 | Volume: 18 | Issue: 2 | Pages: 250-261

10.1111/hex.12027 | PMID 23279082 Get It

Abstract Background Although many probiotic products are currently available in yogurt or pill form in the United States ( US ), there is uncertainty surrounding the structure of regulation of these products. As more therapeutic probiotics are developed, changes to existing regulatory process in the United States may be required to meet the needs of patients and users in the population. Objective This study examined how patients with chronic gastrointestinal ( GI ) diseases view the regulation of probiotics. Design We conducted a multi‐site qualitative study consisting of focus groups of patients with chronic gastrointestinal diseases at three tertiary hospitals: at [institutions removed for blinded review]. Results We conducted 22 focus groups with 136 patients with major gastrointestinal ( GI ) diseases between March and August 2009. Participants were not familiar with the existing regulation of probiotic products but wanted assurances of accurate labelling of strain as well as safety. Participants raised concerns that regulation of probiotics might be accompanied by greater costs, reduced access and increased involvement of pharmaceutical companies. Although participants voiced significant doubt of government regulators, they felt that products containing genetically modified probiotic strains should have oversight comparable to that of pharmaceutical drugs. Discussion and conclusion If GI patient perspectives are indicative of public perceptions of therapeutic probiotics in the United States, consumers may expect more rigorous regulation in the future while simultaneously wanting low costs, easy access and low involvement of pharmaceutical companies. Manufacturers, translational scientists, clinicians and regulators should be sensitive to consumer attitudes when designing, testing and regulating new therapeutic probiotics.
The Establishment of Research Ethics Consultation Services (RECS): An Emerging Research Resource
Sharp, Richard R. , Ottenberg, Abigale L., Reider, Carson, Wilfond, Benjamin S. , McCormick, Jennifer Blair , Taylor, Holly A. , Sharp, Richard R

Mayo Clinic

Clinical and Translational Science | December 6, 2012 | Volume: 6 | Issue: 1 | Pages: 40-44

10.1111/cts.12008 | PMID 23399088 Get It

AbstractEmphasis on translational research to facilitate progression from the laboratory into the community also creates a dynamic in which ethics and social policy questions and solutions are ever pressing. In response, academic institutions are creating Research Ethics Consultation Services (RECS). All Clinical Translational Science Award institutions were surveyed in early 2010 to determine which institutions have a RECS in operation and what is their composition and function. Of the 46 institutions surveyed, 33 (70%) have a RECS. Only 15 RECS have received any consult requests in the last year. Issues that are common among these relatively nascent services include relationships with institutional oversight committees, balancing requestor concerns about confidentiality with research integrity and human subjects protection priorities, tracking consult data and outcomes, and developing systems for internal evaluation. There is variability in how these issues are approached. It will be important to be attentive to the institutional context to develop an appropriate approach. Further data about the issues raised by requestors and the recommendations provided are necessary to build a community of scholars who can navigate and resolve ethical issues encountered along the translational research pathway. Clin Trans Sci 2013; Volume 6: 40–44
Faculty Opinions recommendation of Spontaneous sharp bending of double-stranded DNA.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 19, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1018859.216465 Get It

Evaluating the Quality of Colorectal Cancer Care in the State of Florida: Results From the Florida Initiative for Quality Cancer Care
Siegel, Erin M. , Jacobsen, Paul B. , Malafa, Mokenge P. , Fulp, William J. , Fletcher, Michelle , Lee, Ji‐Hyun , Smith, Jesusa Corazon R., Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George , Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Shibata, David , Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | July 19, 2012 | Volume: 8 | Issue: 4 | Pages: 239-245

10.1200/jop.2011.000477 | PMID 23180990 Get It

Although the quality of care delivered within the Florida Initiative for Quality Cancer Care practices seems to be high, several components of care were identified that warrant further scrutiny on a systemic level and at individual centers.
Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy
Park, Soon J., Milano, Carmelo A. , Tatooles, Antone, Rogers, Joseph G. , Adamson, Robert, Steidley, D. Eric , Ewald, Gregory A. , Sundareswaran, Kartik S., Farrar, David J. , Slaughter, Mark S.

Mayo Clinic

Circulation: Heart Failure | January 27, 2012 | Volume: 5 | Issue: 2 | Pages: 241-248

10.1161/circheartfailure.111.963991 | PMID 22282104 Get It

Background— The HeartMate II (HMII) destination therapy (DT) trial demonstrated significant improvements in outcomes in continuous-flow left ventricular assist devices compared with patients implanted with the pulsatile-flow HeartMate XVE. The primary hypothesis of the current study is that trial patients enrolled after the initial data cohort would have better clinical outcomes. Methods and Results— Two hundred eighty-one patients who underwent HMII for DT from May 2007 to March 2009 (Mid Trial [MT] group) were compared with the initial 133 HMII patients from March 2005 to May 2007 (Early Trial [ET] group). Patient entry criteria were the same during the 2 time periods. Survival, adverse events, and quality of life were compared between the 2 groups. Baseline characteristics were similar between the groups. Compared with the ET group, patients in the MT group had reduced adverse event rates for bleeding requiring transfusions (1.66 versus 1.13 events per patient-year, P <0.001), sepsis (0.38 versus 0.27, P =0.025), device-related infections (0.47 versus 0.27, P <0.001), and hemorrhagic stroke (0.07 versus 0.03, P =0.01). Other event rates were similar between groups including ischemic stroke (0.06 versus 0.05 events per patient-year, P =0.57). Survival at 1 year in the MT group was 73% versus 68% in the ET group ( P =0.21). Additionally, there was a significant reduction in deaths caused by hemorrhagic stroke ( P =0.01). Quality of life improvements were significant in both the groups ( P <0.001). Conclusions— The benefit of DT therapy with the HMII is confirmed in subsequent trial patients, with improved adverse event rates and a strong trend for improvements in survival. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00121485.